Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...
Advertisement Specific types of immune cells unleashed by cancer immunotherapy appear to cause myocarditis, an ...
The heart tissue showed upregulation of molecular pathways that help recruit and retain immune cells involved in inflammation ...
TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...
Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a ...
Recent analysis from the National Cancer Database (NCDB) reveals a significant uptick in immunotherapy (IO) use for advanced ...
The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...
Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback